FATE THERAPEUTICS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Fate Therapeutics Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2012 to Q3 2024.
  • Fate Therapeutics Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$47.7M, a 5.55% decline year-over-year.
  • Fate Therapeutics Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$178M, a 2.92% decline year-over-year.
  • Fate Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$161M, a 42.9% increase from 2022.
  • Fate Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$282M, a 32.8% decline from 2021.
  • Fate Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$212M, a 22.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$178M -$47.7M -$2.51M -5.55% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$176M -$38.4M +$14.3M +27.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$190M -$48M -$29.1M -154% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$161M -$44.1M +$12.2M +21.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 -$173M -$45.2M +$38.4M +45.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$212M -$52.8M +$23.4M +30.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$235M -$18.9M +$46.8M +71.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$282M -$56.4M +$12.3M +17.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 -$294M -$83.6M -$40.3M -93% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$254M -$76.1M -$21M -38% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$233M -$65.7M -$20.6M -45.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$212M -$68.6M -$15.5M -29.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$197M -$43.3M +$15.4M +26.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$212M -$55.1M -$27.1M -96.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$185M -$45.1M -$11.6M -34.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$173M -$53.1M -$24.8M -87.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$149M -$58.7M -$32.1M -121% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$117M -$28.1M -$4.59M -19.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$112M -$33.5M -$13.8M -69.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$98.1M -$28.3M -$12.3M -76.6% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$85.9M -$26.6M -$9.83M -58.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$76M -$23.5M -$3.82M -19.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$72.2M -$19.8M -$5.63M -39.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$66.6M -$16M -$3.53M -28.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$63.1M -$16.8M -$6.1M -57.1% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$57M -$19.7M -$10M -104% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$47M -$14.1M -$4.01M -39.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$43M -$12.5M -$4.56M -57.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-05
Q3 2017 -$38.4M -$10.7M -$1.95M -22.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-05
Q2 2017 -$36.4M -$9.65M -$1.24M -14.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-05
Q1 2017 -$35.2M -$10.1M -$1.75M -20.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-05
Q4 2016 -$33.5M -$7.94M -$494K -6.63% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-05
Q3 2016 -$33M -$8.74M -$1.85M -26.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-05
Q2 2016 -$31.1M -$8.41M -$629K -8.09% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-05
Q1 2016 -$30.5M -$8.38M -$496K -6.29% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-05
Q4 2015 -$30M -$7.45M -$1.21M -19.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$28.8M -$6.89M -$283K -4.29% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$28.5M -$7.78M -$1.71M -28.2% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$26.8M -$7.88M -$901K -12.9% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$25.9M -$6.23M -$494K -8.61% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-03
Q3 2014 -$25.4M -$6.6M -$530K -8.73% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-03
Q2 2014 -$24.9M -$6.07M -$533K -9.63% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-03
Q1 2014 -$24.3M -$6.98M -$3.43M -96.7% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-03
Q4 2013 -$20.9M -$5.74M -$1.58M -38.1% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$19.3M -$6.07M -$1.96M -47.7% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$17.4M -$5.53M -$2.8M -102% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$14.6M -$3.55M -$314K -9.71% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 -$14.2M -$4.16M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$4.11M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$2.74M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$3.23M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.